| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| PROVECTUS BIOPHARMACEUTICALS, INC. | CFO | Stock Options (Right to Buy) | 4,197,890 | 02 Dec 2024 | Direct | ||
| PROVECTUS BIOPHARMACEUTICALS, INC. | CFO | 8% Unsecured Convertible Promissory Note due 2022 | $125,000 | 28 Feb 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 02 Dec 2024 | 1 | $0 | 4 | CFO | 04 Dec 2024, 21:24 |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 28 Feb 2024 | 1 | -$50,000 | 4 | CFO | 29 Feb 2024, 09:22 |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 02 Feb 2024 | 1 | -$25,000 | 4 | CFO | 06 Feb 2024, 15:16 |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 16 Aug 2021 | 1 | +$200,000 | 4 | CFO | 18 Aug 2021, 16:05 |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 17 Jun 2021 | 3 | $0 | 4 | CFO | 22 Jun 2021, 17:26 |